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ABSTRACT Anxiety is an important comorbidity in chronic obstructive pulmonary disease (COPD). We
investigated if cognitive behavioural therapy (CBT), delivered by respiratory nurses, reduced symptoms of
anxiety and was cost-effective.
Patients with COPD and anxiety were randomised to CBT or self-help leaflets. Anxiety, depression and
quality of life were measured at baseline, 3, 6 and 12 months. A cost-effectiveness analysis was conducted
from a National Health Service hospital perspective and quality-adjusted life-years estimated using the
EuroQol-5D questionnaire.
In total, 279 patients were recruited. Group mean change from baseline to 3 months in the Hospital
Anxiety and Depression Anxiety Subscale was 3.4 (95% CI 2.62–4.17, p<0.001) for the CBT group and
1.88 (95% CI 1.19–2.55, p<0.001) in the leaflet group. The CBT group was superior to leaflets at 3 months
(mean difference in the Hospital Anxiety and Depression Anxiety Subscale was 1.52, 95% CI 0.49–2.54,
p=0.003). Importantly, the CBT intervention was more cost-effective than leaflets at 12 months,
significantly lowering hospital admissions and attendance at emergency departments.
CBT delivered by respiratory nurses is a clinically and cost-effective treatment for anxiety in patients
with COPD relative to self-help leaflets.
@ERSpublications
Cognitive behavioural therapy (CBT) delivered by respiratory nurses is clinically effective and
cost-effective for patients with chronic obstructive pulmonary disease and symptoms of anxiety
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COPD
Introduction
Chronic obstructive pulmonary disease (COPD) is one of the most important chronic diseases affecting
over 210 million people worldwide [1]. Anxiety and depression are major comorbidities in COPD
associated with high morbidity, disability, healthcare expenditure and mortality [2, 3]. The under diagnosis
and under treatment of anxiety and depression in COPD is common and can adversely affect patient
outcomes [4–6]. Anxiety and depression have a significant impact on physical functioning, breathlessness,
quality of life, exacerbation rates, use of healthcare resources, length of hospital stay, readmission rates and
mortality [2–4, 7–11]. Patients with psychological difficulties are less able to manage symptoms [12]
and are less likely to be physically active [4] or attend pulmonary rehabilitation, an evidence-based
intervention, which is a key strategy for people with chronic respiratory conditions [13].
Guidelines for the treatment of anxiety and depression recommend psychological treatment (cognitive
behavioural therapy (CBT), counselling and self-help approaches) and pharmacological treatment, or a
combination of both [14, 15]. CBT is a “talking” treatment, which explores the link between a patient’s
situation, physical symptoms, thoughts, emotions and behaviour.
Traditionally, treatment for anxiety and depression is provided by mental health professionals, but this
may not encompass the needs of COPD patients where complex physical health problems and mental
health issues are interrelated. There are also barriers to accessing mental health support including
perceived stigma and unwillingness to engage with mental health services, lack of prioritisation compared
with physical healthcare [16], increasing demand and limited resources [16]. While CBT is an
evidence-based intervention for anxiety and depression generally, the effectiveness of CBT in the context
of COPD is unclear [17, 18]. The need for high-quality research with sufficient power to test the potential
benefit of CBT in COPD has been recommended [17–19]. We identified anxiety as the most appropriate
primary outcome due to the frightening nature of breathlessness and the link with increased use of
healthcare resources [20]. We designed a pragmatic randomised controlled trial (RCT) with sufficient
power to address our hypothesis that one-to-one CBT sessions, delivered by respiratory nurses, could lead
to a reduction in anxiety symptoms as measured by the Hospital Anxiety and Depression Scale (HADS)
Anxiety Subscale [21], and could be a cost-effective intervention.
Materials and methods
Study design
A pragmatic RCT was conducted according to ethical principles outlined in the Declaration of Helsinki
2008 and following the methods set out in a published protocol (ISCRTN 55206395) [22]. The study was
approved by the National Research Ethics Service (11/NE/0025).
Patients
Study accessibility was maximised with pragmatic inclusion and exclusion criteria to mirror real life
clinical settings (table 1).
Study interventions
A remote computerised program and concealed sequence generation was used to randomise patients to an
active control of self-help leaflets addressing anxiety management [24, 25] or a brief CBT intervention plus
self-help leaflets [24, 25]. All patients received standard medical care (spirometry, medical review,
pharmacological treatment (e.g. respiratory medication, antidepressants and anxiolytics)) and pulmonary
rehabilitation if eligible.
TABLE 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
A confirmed diagnosis of COPD (FEV1/FVC
ratio <70% [5]
All levels of COPD disease severity
(mild–very severe)
HADS-Anxiety Subscale score of ⩾8
Consent to 2–6 sessions of CBT [23]
A HADS-Anxiety Subscale score of <8
Known psychiatric history such as psychosis
Patients currently receiving psychological talking therapy
including CBT treatment
Patients with cognitive impairment (e.g. dementia)
Patients involved in any other interventional clinical trial
COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; HADS: Hospital Anxiety and Depression Scale; CBT: cognitive behavioural therapy.
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The brief CBT intervention was developed and refined before the study commenced (the Lung Manual) [26].
Between two and six fortnightly CBT sessions were undertaken, which is recommended for a brief
intervention [23]. Sessions were conducted either in clinic or at home and lasted ∼30 min. The number of
sessions suggested and timescale for these was then co-developed with the patients depending on the
patients’ individual response to treatment to manage symptoms based on their subjective feedback, HADS
questionnaire results and patient preference. The respiratory nurses used cognitive and behavioural
techniques to reduce symptoms of anxiety. Key components of the treatment are summarised in
supplementary table S1.
Nurse training
Four respiratory nurses with varying clinical experience post-qualification (1–30 years) were recruited to
deliver the intervention. Two nurses had completed a post-graduate diploma in CBT. Two nurses
completed 3 days CBT training (table 2).
The nurses attended the first 2 days training then returned to clinical practice for 6 weeks to consolidate
their skills with patients within their clinical setting. On day three the nurses presented a case study to
demonstrate learning and application of CBT skills. The nurses and a patient carer from the Trial Steering
Committee attended a half day training on the Lung Manual.
To formally assess CBT skills and treatment fidelity, random CBT sessions were video-recorded and rated
using the Cognitive First Aid rating scale (CFARS) 10-item scale [27]. The CFARS scores range from zero
(poor skills and competency) to six (high level of skill and competency). Scoring four or above is
considered an acceptable level of skills and expertise [15]. The nurses received monthly clinical supervision
(with K.H.M.) who developed the intervention. This is essential to gain further skill and maintain
confidence [27].
Outcome measurements
The primary outcome for anxiety was the change in the group mean HADS-Anxiety Subscale at 3 months
from baseline. The HADS is a brief self-completed questionnaire, validated in COPD [28, 29]. Scores of
8–10 indicates mild symptoms, 11–14 moderate and 15–21 severe [28]. The minimal clinically important
difference (MCID) of HADS-Anxiety is 1.32 and 1.40 for HADS-Depression [29]. A difference of the
HADS (anxiety or depression) of 1.5 is recommended in COPD patients corresponding to a change from
baseline of ∼20% [29].
Secondary outcomes were the change in group mean HADS-Anxiety Subscale at 6 and 12 months from
baseline and group mean change in the HADS-Depression Subscale, COPD Assessment Test (CAT) [30]
and EuroQol-5D (EQ-5D) 3L [31] at 3, 6 and 12 months from baseline. The CAT is a disease specific
health status questionnaire containing eight items and has been validated in COPD [30]. A change of two
or more units suggests a clinically significant difference in COPD health status [32]. The EQ-5D 3L is a
generic quality of life questionnaire, which is commonly used for cost-effectiveness analysis of
interventions using quality-adjusted life-years (QALYs). The QALY incorporates the impact on both the
quantity and quality of life. The EQ-5D 3L is a reliable and valid tool for COPD patients [33]. Staff
collecting the outcome data were blinded to the intervention.
TABLE 2 Content of cognitive behavioural therapy (CBT) nurse training
Day 1 Day 2 Day 3
Course aims Revision Feedback from homework
Basic introduction to CBT Feedback from homework Revision
Using CBT in physical health setting Goal setting Case presentations
Anxiety Cognitive techniques Supervision
Panic Behavioural techniques Course evaluation
Depression Case study
Screening for anxiety and depression Practical session (theory into practice)
Risk management (suicide assessment) Summary
Formulation of patients difficulties Homework
Socratic questioning and guided discovery
Unhelpful thinking
Practical session
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Statistical analysis
The sample size calculation was based on a two-sample t-test with a pooled standard deviation of four for
the HADS-Anxiety Subscale based on a local sample of patients with COPD. Complete outcome data on
112 patients per group was required to detect a standardised difference of 0.375 (equivalent to a 20%
improvement in HADS-Anxiety score) with 80% power at the 95% significance level [29].
An intention-to-treat analysis was undertaken. Data were analysed for all participants, for whom an
outcome was available, according to the treatment group to which they were randomised. Means and
percentages were used for descriptive statistics. For the primary outcome, groups were compared using an
independent t-test. A secondary analysis was performed using multiple imputation for missing data.
Multiple imputation is a statistical technique for analysing incomplete data [34]. Fisher’s exact test was
used to compare categorical data where applicable, tests were two-tailed and significance was set at a level
of p<0.05.
Results
From June 2011 to October 2014, 1518 COPD outpatients were screened. We found 898 (59%) of patients
had a HADS-Anxiety Subscale of eight or more. An outline of patient flow can be found in figure 1.
Baseline characteristics are presented in table 3. The mean age for all patients was 66 years (range
41–88 years). All patients recruited had symptoms of anxiety with a HADS-Anxiety Subscale of eight or
above. The mean HADS-Anxiety Subscale was 12.3 for the CBT group and 12.0 for the self-help leaflet
group at baseline, suggesting moderate anxiety symptoms [11]. 64% of patients reported moderate to
severe symptoms of anxiety. Coexisting symptoms of depression were reported in 186 (67%): 94 in the
CBT group (68%) and 92 (66%) in the self-help leaflet group at baseline. There appeared to be no
correlation between HADS-Anxiety or Depression scores at baseline and severity of lung function based
on forced expiratory volume in 1 s (FEV1) % predicted.
Patients assessed for eligibility
Excluded (n=1239)
  Not meeting inclusion criteria (n=802)
    HADS-Anxiety <8 (n=620)
    Major psychiatric problem/current psychological treatment (n=86)
    FEV1/FVC ratio <70% (n=41)
    Not COPD (n=43)
    In another clinical study (n=4)
    Cognitive impairment (n=24)
  Unable to contact (n=24)
  Declined to participate (n=392)
  Requested CBT (n=12)
  Died (n=1)
  Out of area (n=8)
Screening
Randomised (n=279)
Allocated to CBT intervention (n=139)
  Received intervention (n=129)
Allocated to active control (n=140)
  Received allocated intervention (n=140)
Enrolment
Allocation
Primary outcome data at 3 months (n=115)
  Died (n=2)
  Dropped out (n=5)
  Lost to follow-up (n=5)
  Withdrawn (n=2)
Primary outcome data at 3 months (n=121)
  Died (n=4)
  Dropped out (n=6)
  Lost to follow-up (n=7)
  Withdrawn (n=2)
Follow-up
Analysis
FIGURE 1 Patient flow diagram. HADS: Hospital Anxiety and Depression Scale; FEV1: forced expiratory volume
in 1 s; FVC: forced vital capacity; COPD: chronic obstructive pulmonary disease; CBT: cognitive behavioural
therapy.
https://doi.org/10.1183/23120541.00094-2018 4
COPD | K. HESLOP-MARSHALL ET AL.
In the CBT group, 10 patients did not receive the allocated treatment due to dropping out or were found
at pretreatment assessment to be ineligible (due to undiagnosed cognitive impairment or undisclosed
formal psychiatric involvement at the time of consent).
Self-reported data was collected at baseline on relevant pharmacological therapy (see supplementary table S2).
In total, 52 (37%) patients had been prescribed antidepressants compared with 47 (34%) from the leaflet
group. Data on pulmonary rehabilitation was collected at baseline and 12 months. 46 patients had
completed pulmonary rehabilitation in the CBT group at baseline and this increased to 64 patients at
12 months. In the leaflet group 50 patients had completed pulmonary rehabilitation at baseline and this
increased to 62 at 12 months.
Anxiety
In total, 236 patients completed the primary end-point of 3 months (85% completion rate). Complete data
were available for 115 patients in the CBT arm and 121 in the leaflet arm. Group mean data for
HADS-Anxiety can be seen in table 4 [29].
The average number of CBT sessions delivered was four, which falls within the recommendations for a
brief intervention [23]. There was a statistically significant improvement in mean HADS-Anxiety scores in
TABLE 3 Baseline characteristics
CBT group Leaflet group Total patients
Subjects n 139 140 279
Mean±SD age years 66±10.2 67±9.6 66.5±9.9
Males/females 61 (44)/78 (56) 67 (48)/73 (52) 128 (46)/151 (54)
Ethnic group, Caucasian 139 (100) 140 (100) 279 (100)
Mean±SD HADS-Anxiety Subscale 12.3±3.19 12.0±2.94 12.2±3.06
HADS-Anxiety Subscale 8–10 51 (37) 49 (35) 100 (36)
HADS-Anxiety Subscale 11–14 52 (37) 63 (45) 115 (41)
HADS-Anxiety Subscale 15–21 36 (26) 28 (20) 64 (23)
Mean±SD HADS-Depression Subscale 9.2±4.0 8.8±3.7 9.0±3.85
Severity of airflow obstruction based on GOLD criteria
Mild 16 (11) 13 (9) 29 (10)
Moderate 44 (32) 47 (34) 91 (33)
Severe 50 (36) 49 (35) 99 (35)
Very Severe 29 (21) 31 (22) 60 (22)
MRC Breathlessness score
0–2 8 (6) 12 (9) 20 (7)
3 25 (18) 19 (14) 44 (16)
4 39 (28) 44 (31) 83 (30)
5 67 (48) 65 (46) 132 (47)
Current smoker 39 (28) 40 (29) 79 (28)
Mean±SD BMI kg·m−2 26±6.4 27±6.0 26.5±6.22
No educational qualifications 100 (72) 103 (74) 203 (73)
Data are presented as n (%), unless otherwise stated. CBT: cognitive behavioural therapy; HADS: Hospital
Anxiety and Depression Scale; GOLD: Global Initiative for Chronic Obstructive Lung Disease; MRC: Medical
Research Council; BMI: body mass index.
TABLE 4 Group mean Hospital Anxiety and Depression (HADS)-Anxiety Subscale at each time
point
Group mean±SD HADS-Anxiety Subscores
Baseline 3 months 6 months 12 months
Cognitive behavioural therapy 12.3±3.19
(n=139)
8.8±4.49
(n=115)
8.6±4.02
(n=93)
8.7±4.06
(n= 93)
Leaflet 12.0±2.94
(n=140)
10.0±4.42
(n=121)
9.7±4.31
(n=99)
10.2±4.33
(n=79)
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the CBT group compared to the self-help leaflet group at 3 months (table 5). For the HADS-Anxiety
Subscale change score, the difference between the two treatment groups is significant at the table wide 0.05
level after applying the sequential Bonferroni method [35].
A secondary outcome was a reduction in symptoms of depression. The mean HADS-Depression Subscale
for the two groups were compared at 3, 6 and 12 months. The CBT arm was statistically significantly better
than the leaflet arm at 3 and 6 months, but this did not reach the MCID (see supplementary table S3).
CBT competency and fidelity
During the study 22 CBT sessions were video recorded and assessed to evaluate adherence to the Lung
Manual and competency delivering the CBT. The validated 10-item CFARS was used [27]. The scoring
system for the items ranges from zero (poor skills and competency) to six (high level of skill and
competency). Scoring four or above is considered an acceptable level of skills and expertise. Average
competency scores for CFARS rating scale are summarised in supplementary table S4. The nurses scored
highly on focus/structure of the CBT, therapeutic relationship and providing feedback to patients.
Health economic analysis
A health economic analysis from a National Health Service (NHS) perspective (hospital setting) was
conducted alongside the RCT to evaluate the cost-effectiveness of the CBT intervention compared to
self-help leaflets [36]. The EQ-5D 3L scores collected at baseline, 3-, 6- and 12-months
post-randomisation were converted into QALYs using the area under the curve method with adjustment
for baseline utility scores [37]. The costs and benefits were not discounted since the timescale of the trial
was 12 months.
NHS costs (including intervention costs and costs of respiratory-related hospital admissions and attendance
at emergency departments) were compared with QALYs using established methods [38]. All resource use
was costed at 2015/2016 prices in GBP. The costs of the CBT intervention comprised of staff time (including
the costs of training to deliver the intervention in terms of staff time, delivering the intervention and
ongoing supervision). Both groups received the self-help leaflet, so we assumed this cost was equal. Unit cost
data were obtained from a combination of local costings and national databases [39, 40].
Based on the EQ-5D missing quality of life observations were assigned using multiple imputation by
chained equation methods using variables related to quality of life including age, gender, marital status
and education [36]. Results are presented using an incremental cost-effectiveness ratio (ICER). To gain an
understanding of the uncertainty surrounding the ICER, a cost-effectiveness acceptability curve was
estimated using a nonparametric bootstrap method on the basis of 5000 replications. This shows the
probability of each comparator being cost-effective given a particular level of the decision maker’s
willingness to pay for an additional QALY [36].
The patients randomised to CBT had fewer hospital admissions and fewer emergency department
attendances (0.6 versus 1.01 and 0.37 versus 1.01, respectively). The CBT intervention cost GBP 175 per
patient (approximately EUR 200), which resulted from extra initial costs being incurred (including the
costs of training to deliver the intervention in terms of staff time, delivering the intervention and ongoing
supervision) relative to the self-help leaflets (95% CI 165–185, p=0.001) (table 6). However, costs were
offset by lower subsequent costs of respiratory hospital admissions with an average mean difference of
GBP 1089 (95% CI −2370–227) (approximately EUR 1247) saved per patient and GBP 63 (95% CI
−121–−7) (approximately EUR 72) lower for emergency department attendances. The results for EQ-5D 3L
show that both groups experienced an increase in QALYs; however, the CBT arm gained more QALYs and
TABLE 5 Differences in mean anxiety from baseline and between groups
Mean improvement from baseline Difference in mean improvement
(95% CI, p-value)CBT group Leaflet group
HADS-Anxiety Subscale at 3 months 3.40 (n=115) 1.88 (n=121) 1.52# (0.49–2.54, p=0.003)
HADS-Anxiety Subscale at 6 months 3.42 (n=101) 2.36 (n=99) 1.05 (−0.04–2.14, p=0.05)
HADS-Anxiety Subscale at 12 months 3.35 (n=93) 1.89 (n=79) 1.43 (0.28–2.66, p=0.016)
CBT: cognitive behavioural therapy; HADS: Hospital Anxiety and Depression Scale. #: the mean difference is higher than the HADS-Anxiety
Score minimal clinically important difference of 1.50 [17].
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was the most effective with an average mean difference of 0.079 (95% CI 0.023–0.140, p=0.008). Thus, the
CBT intervention was less expensive and more effective than self-help leaflets alone.
The results suggest that the intervention is a dominant strategy relative to self-help leaflets. To gain an
understanding of the uncertainty surrounding the dominance of CBT, a cost-effectiveness acceptability
curve (CEAC) was estimated using a nonparametric bootstrap method based on 5000 replications [36].
The results of the parametric CEAC and the cost-effectiveness plane are presented in figure 2. At all
thresholds for the willingness to pay for a QALY, CBT has a higher probability of being cost-effective
compared with self-help leaflets (table 7). For values over GBP 5000 (approximately EUR 5727), the
probability that the intervention is cost-effective is 100%.
Overall, the CBT intervention was less expensive (driven by the reduction in resource use with lower
hospital admissions and a statistically significant reduction in emergency department attendances) than
self-help leaflets. These results suggest there is minimal uncertainty that CBT is more effective and less
expensive than self-help leaflets.
Discussion
In the largest study to date, we hypothesised that one-to-one CBT sessions delivered by respiratory nurses
could lead to a reduction in anxiety as documented by the HADS-Anxiety Subscale [21] and could be
cost-effective across a range of COPD severities. We found a significant number of patients screened (59%)
had symptoms of anxiety. This prevalence is higher than an earlier systematic review and meta-analysis
that identified anxiety symptoms in 46% of patients [3]. Over half of patients also had comorbid
symptoms of depression.
The results indicate CBT delivered by respiratory nurses was clinically effective in patients with COPD and
comorbid symptoms of anxiety. The CBT intervention was both statistically and clinically superior to
self-help leaflets in the primary outcome measured at 3 months with a difference of 1.52 on the
HADS-Anxiety Subscale at the primary end-point [29].
The CBT intervention was also cost-effective. While the CBT intervention incurred initial costs for
training and supervision, these costs were offset by lower subsequent costs for respiratory admissions and
emergency department attendances over 12 months. The results of the EQ-5D 3L analysis also show that
while both groups experienced an increase in QALYs, the CBT arm gained more and was the most
effective. We noted that there was no correlation between lung function (FEV1 % predicted) and
HADS-Anxiety Subscale, which may suggest patients with milder COPD treated within primary care
services may benefit from this clinically and cost-effective treatment. Potential mechanisms underlying
reduced healthcare utilisation include better self-management of frightening physical symptoms such as
breathlessness, amplified by anxiety. As patients did not have to have symptoms of depression at baseline,
the benefit of CBT cannot be concluded from this study. We believe the HADS-Depression data are
interesting and support an effect of CBT on HADS-Depression, but further research is needed.
Strengths and limitations
The strengths of this pragmatic multicentre study are that it was adequately powered and only included
patients with validated objective measurements of anxiety symptoms at baseline. We also included all
levels of COPD severity to improve generalisability. Further strengths are that we used processes to
minimise bias from randomisation, data collection and data analysis. This addresses the limitations of
previous studies [17]. The results were confirmed using multiple imputation for missing data suggesting
bias due to dropouts was unlikely.
Complex behaviour change interventions are often poorly described when reported, impairing the ability
to replicate the research [41]. A detailed manual and training programme were developed to allow its use
to be replicated.
A comprehensive health economic evaluation was conducted according to best practice methods. Our
results show the CBT intervention was effective in gaining QALYs, within the National Institute for Health
and Care Excellence (NICE) threshold, of GBP 30000/EUR 34000, often applied in the UK to determine if
an intervention is acceptable. At this level, the CBT intervention would be a preferable intervention and
cost-effective compared to self-help leaflets [42].
Several limitations of this study are acknowledged. Caution should be used when interpreting the results of
HADS questionnaire. The HADS questionnaire has been shown to be a reliable measure of emotional
distress but not in predicting probable presence or “caseness” of anxiety. We cannot conclude if there is a
specific HADS threshold where the intervention is more or less likely to be effective as we were not
powered for subgroup analysis. Although the majority of COPD costs relate to hospital admissions, we do
https://doi.org/10.1183/23120541.00094-2018 7
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not have primary care attendance data. This was beyond the scope of our data collection resources. Wider
societal cost analyses, including primary and community care costs, to observe any cost shifting between
sectors would have been beneficial in assessing the potential wider benefits of the intervention.
There are challenges to implementing CBT for psychological morbidity associated with physical illnesses
including cost, the availability of trained CBT therapists and patient reluctance to engage in psychological
treatments [27]. In our study, 392 (26%) eligible patients declined to take part in the trial. While this is
generally in line with clinical trials engagement, the rates of engagement with CBT outside of a clinical
trial are unknown. Screening for comorbid anxiety symptoms in the clinic and having a nurse skilled in
both respiratory and CBT management may remove stigma or other barriers to CBT, improve engagement
and allow more holistic care.
During the treatment phase, it was not possible to blind participants or the nursing staff delivering the
intervention. To reduce bias, we had an independent and blinded team collecting follow-up data. We did
not include a placebo group; having identified anxiety symptoms as an issue, we felt it was unethical to
offer no treatment. Our control arm was self-help leaflets.
Our pragmatic study shows that tailored CBT approaches can be developed for COPD patients, helping to
manage difficult symptoms of anxiety, which are intrinsically linked with breathlessness [43]. This is the
TABLE 6 Costs and QALYs of cognitive behavioural therapy (CBT) intervention and self-help leaflets
CBT intervention
mean (95% CI)
Leaflets
mean (95% CI)
Bootstrapped mean difference
(95% CI, p-value)
Intervention costs GBP 175 (165–185) 175 (165–185, p=0.001)
Number of respiratory admissions 0.6 (0.35–0.85) 1.01 (0.61–1.4)
Costs of respiratory admissions GBP 1601 (936–2267) 2689 (1632–3746) −1089 (−2370–227, p=0.076)
Number of ED attendances 0.37 (0.16–0.59) 0.81 (0.48–1.14)
Costs of ED attendances GBP 55 (23–86) 118 (70–166) −63 (−121–−7, p=0.036)
Total mean cost GBP 1830 (1143–2517) 2807 (1706–3909) −997 (−2349–228, p=0.158)
Mean difference in effect QALYs 0.079 (0.023–0.140, p=0.008)
ED: emergency department; QALYs: quality-adjusted life-years.
0
500
1000
1500
–500
–1000
–1500
–2000
–2500
–3000
–3500
In
cr
em
en
ta
l c
os
t G
B
P
Incremental QALYs
0.000
Quadrant 1 Quadrant 2
Quadrant 3 Quadrant 4
–0.050 0.050 0.100 0.150 0.200
CBT versus usual care
Average
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largest trial of CBT in COPD, to date, and the first study to demonstrate that respiratory nurses can be
trained to undertake and effectively deliver a cost-effective brief CBT intervention to reduce symptoms of
anxiety in COPD patients. Training respiratory staff can lead to better recognition and treatment of
breathlessness and anxiety symptoms, in patients who otherwise may not have engaged with mental health
services. With greater availability of CBT trained respiratory nurses, routine screening and treatment for
symptoms of anxiety in patients with COPD is feasible and should be incorporated into clinical care
pathways, addressing the current lack of resources to address mental health needs [16]. Finally, further
studies are needed to identify how to incorporate CBT into routine clinical care and identify if the
intervention can be successfully replicated for those treated in primary care.
Conclusion
This study shows that a brief CBT intervention, uniquely delivered by respiratory nurses, was clinically
effective at reducing anxiety symptoms and was cost-effective. Costs were reduced by lower resource use
with lower hospital admissions and a reduction in emergency department attendances. Respiratory nurses
with dual respiratory and CBT skills can address common comorbid symptoms of anxiety that were
previously under treated. CBT should be incorporated into routine clinical care pathways.
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